Left ventricular hypertrophy in hypertension is an independent predictor for sudden death, ventricular arrhythmias, myocardial ischaemia, coronary heart disease, and heart failure.`-9 These relations have proved true whether the hypertrophy is detected by electrocardiography or by the much more sensitive technique of echocardiography. It seems logical that regression of left ventricular hypertrophy would be beneficial, but, as yet, few clinical data support this contention beyond a limited experience from the Framingham study. Antihypertensive treatments might differ in their ability to promote regression of left ventricular hypertrophy independently of their blood pressure lowering effect. There is a powerful theoretical basis suggesting that inhibition of angiotensin converting enzyme (ACE), with consequent reduction in plasma and tissue concentrations of angiotensin II, may be superior in promoting regression of left ventricular hypertrophy. Studies in animal models of hypertension and meta-analyses of trials of drug treatment in human hypertension are not entirely concordant, but overall they support a major role for ACE inhibitors in reducing left ventricular hypertrophy.
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Left ventricular hypertrophy as risk factor The two widely used techniques for detecting left ventricular hypertrophy are electrocardiography and echocardiography. Echocardiography is by far the more sensitive, detecting hypertrophy in 14% and 18% of men and women respectively in the subjects of the Framingham heart study. By contrast, electrocardiographic features of left ventricular hypertrophy were present in only 2/9% of men and 1-5% of women in this population. ' (over 125 g/m2) in 27% of patients. '5 In the same study cardiovascular events occurred in a higher proportion of patients with left ventricular hypertrophy than in those without (26% v 12%, P < 0-0 1). Cardiovascular death was 28 times more common in the group with left ventricular hypertrophy (14% v 0-5%, P < 0 00 1), all cause mortality being eight times more common ( /6% v 2%, P < 0.01). Patients with normal left ventricular geometry suffered no cardiac death and only 1 1% suffered a morbid event in contrast with those with concentric hypertrophy, who had a mortality of 21% and a morbidity of 31%. In a larger population of more than 3000 people over 40 who were free of overt clinical cardiovascular disease and were followed up for four years, 208 cardiovascular end organ events occurred, including 37 cardiovascular deaths and 124 deaths from all causes.9 The relative risk of cardiovascular death was significantly increased for every 50 g-increment in left ventricular mass (relative risk 1-73 for men and 2-12 for women). For all causes of death the corresponding relative risks were 1-49 in men and 2-01 in women. In a multivariate analysis the adverse prognostic significance of increased left ventricular mass was independent of age, diastolic blood pressure, pulse pressure, antihypertensive treatment, smoking, presence or absence of diabetes, presence or absence of obesity, lipid profile, and electrocardiographic evidence of left ventricular hypertrophy.
Recent studies using electrocardiographic criteria for detecting left ventricular hypertrophy confirm earlier indications that electrocardiographic hypertrophy is an independent indicator of both cardiovascular and all cause mortality. In a population of nearly 5000 patients undergoing coronary angiography over 13 years electrocardiographic evidence of left ventricular hypertrophy was present in 5.2%. 16 per 1000 patient years. This association of electrocardiographic left ventricular hypertrophy with increased mortality was independent of age, blood pressure, and smoking.
The mechanism linking left ventricular hypertrophy with increased morbidity and mortality is uncertain. Possibilities include a mismatch of blood supply to tissue mass, leading to comparatively ischaemic subendocardial tissue. Basal myocardial oxygen demand may be increased because of increased wall mass and some increase in wall stress. There may be increased susceptibility to ventricular arrhythmia, which may be related to an increased component of fibrous tissue within the myocardium. Coronary reserve is reduced, leading to a lowered threshold for induction of ischaemia in the presence of stressors such as exercise and short term falls or rises in blood pressure.
Thus, left ventricular hypertrophy is an undeniably undesirable feature in hypertension, and it seems logical that regression of hypertrophy might improve prognosis. However, clinical data to support this contention are sparse. Only one study has provided prospective evidence of the benefits of regression of left ventricular hypertrophy. Data from the Framingham study showed a fall of 25% in cardiovascular mortality in a subgroup with reduction in electrocardiographic left ventricular hypertrophy compared with a similar group without such regression during follow up of over four years. '8 Furthermore, in 166 patients with hypertension followed up for five years cardiovascular events occurred in only 6% of those whose left ventricular mass decreased or was unchanged compared with 16% with increased left ventricular hypertrophy. ' 11.46 Hence, activation of the circulating reninangiotensin system is not an essential factor for expression of left ventricular hypertrophy in hypertension.
The role of the cardiac tissue reninangiotensin system in patients with left ventricular hypertrophy is unknown. Alderman et al found that in patients with hypertension, renin profiles (obtained by plotting plasma renin activity against urinary excretion of sodium) were independently associated with subsequent risk of myocardial infarction.47 Other workers found no such association between plasma renin activity and myocardial infarction in normotensive men.48
This raises the question of whether the association of activation of the renin-angiotensin system and coronary events in essential hypertension is mediated by promotion of left ventricular hypertrophy.
A further link between the reninangiotensin-aldosterone system and cardiovascular risk has appeared in recent studies indicating that a particular deletion polymorphism in the angiotensin converting enzyme gene is associated with the risk of myocardial infarction, ischaemic cardiomyopathy, congestive cardiomyopathy, and hypertrophic cardiomyopathy. 49 S 26 while the angiotensin II receptor blocker did reduce blood pressure but was less effective in reducing cardiac hypertrophy. Further studies by this group indicated that ramipril was able to prevent left ventricular hypertrophy and myocardial fibrosis without blood pressure reduction over a one year period in rats. 67 Liebson reviewed over 60 clinical studies using echocardiographic measurement of left ventricular mass. On average, only 10-15 subjects were included in each study. He pointed out the lack of studies in patients with clearly established disease-that is, clearcut moderate or severe left ventricular hypertrophy with complications such as coronary disease-and highlighted the need for a study which followed up a substantial number of people over a long treatment period. Ninety per cent of studies had a follow up period of less than one year. The longest running study with the largest number followed up in a single study ( group.bmj.com on October 14, 2017 -Published by http://heart.bmj.com/ Downloaded from remained excellent.77 Dunn et al followed up eight patients treated with enalapril for only 12 weeks and found a significant reduction in left ventricular mass index and no impairment of left ventricular contractility.78 Nakashima et al studied seven patients receiving enalapril and undergoing echocardiography and radionuclide studies at baseline, at 5 days, and after one, three, and seven months of treatment.79 Left ventricular mas was reduced significantly at three and seven months by 10% and 12% respectively. At the time these three small studies and several others were published in the early 1 980s only methyldopa and a blocking drugs had been reported as inducing regression of left ventricular hypertrophy when used as a single treatment in hypertension. [80] [81] [82] [83] Previously, when combination treatment had been seen to induce regression of left ventricular hypertrophy, the combination almost always included a sympatholytic agent or a a blocker. [84] [85] [86] Few data are available comparing the effects of different ACE inhibitors. Garavaglia et al studied 30 patients with mild to moderate hypertension receiving captopril, lisinopril, or enalapril for 10-12 weeks.87 Left ventricular mass was reduced in all three groups but rather more with enalapril (29%) than with either of the two other agents (1 4% and 12% respectively). But the number of subjects in each group was small (8) (9) (10) (11) (12) and baseline values for left ventricular mass were greatest in the enalapril group. Grandi et al found that captopril and perindopril had similar effects on both blood pressure and left ventricular mass.88 Hence, as yet, there are no unequivocal data indicating that any particular ACE inhibitor or class of ACE inhibitors is superior to another in terms of the ability to induce regression of left ventricular hypertrophy.
Although In one of the few studies that specifically examined patients with clearly established left ventricular hypertrophy 34 patients, all with poorly controlled blood pressure despite treatment with a 1 blocker and diuretic, had either captopril or minoxidil randomly added to their treatment.9' Mean interventricular septal thickness was 17-4 mm and 15-5 mm for the captopril and minoxidil groups respectively. Posterior wall thickness was 14-5 mm and 14 1 mm respectively. Left ventricular mass index was 236 g/m2 and 212 g/m2 for the two groups. Thus severe left ventricular hypertrophy was present. Baseline blood pressures were similar in the two groups. Left ventricular wall thickness and mass index clearly declined in the group treated with captopril, whereas the opposite occurred in those receiving minoxidil despite similar reductions in blood pressure. These data contrast the effect of an ACE inhibitor against minoxidil when both were combined with two other antihypertensive agents. Nevertheless, the differences in response are quite striking.
At least one study suggests that the ability of ACE inhibitors to induce regression of left ventricular hypertrophy is independent of cardiac innervation. Angermann et al reported regression of left ventricular hypertrophy on echocardiography in 10 patients with hypertension after cardiac transplantation.92
Treatment over one year with enalapril and frusemide with or without verapamil reduced blood pressure substantially and significantly reduced left ventricular mass.
With the shortcomings of previous studies in mind, Dahlof 
mass. The authors concluded that an ACE inhibitor is significantly more effective than a diuretic in reducing left ventricular mass. Before this study trials of ACE inhibition were confined to open studies usually in previously treated patients. Despite its strengths, the study by Dahlof and Hansson still includes only 28 patients, or 14 
Not all clinical trials examining the effect of ACE inhibitors in hypertension with left ventricular hypertrophy have positive results. In view of the described frailties of the database and the probability that studies with negative results are not as readily published as those with positive results, these contrary findings cannot be ignored. Shahi et al studied 20 previously untreated hypertensive patients receiving captopril with or without a diuretic for six months and found reduced blood pressure (15/20) variate analysis was applied to compensate for differences between studies in mean baseline indices of cardiac structure and in duration of follow up, the adjusted percentage change in left ventricular mass showed clear overlap in confidence intervals between ACE inhibitors, a blockers, calcium antagonists, and diuretics (figure). Thus, although this meta-analysis provides strong suggestive evidence, based on trends, of an enhanced effect of ACE inhibition on regression of left ventricular hypertrophy, the data are by no 
